ActHIB®

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Haemophilus Influenzae Type bInfections, MeningococcalNeisseria Meningitidis

Phase 2

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

CompletedNCT00127855

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2003-03-01End: 2004-02-12Updated: 2018-08-27

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

CompletedNCT00134719

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2005-04-11End: 2007-02-21Updated: 2018-07-19

Phase 3

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

CompletedNCT00614614

GlaxoSmithKlineInfections, Meningococcal

Start: 2008-02-13End: 2009-09-17Updated: 2018-09-21

Related Papers

Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae–N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy

Vaccine2014-08-2213 citations

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.

2012-08-017 citations